Higher-Risk Myelodysplastic Syndrome (HR-MDS)

specific

Myelodysplastic syndrome with a score of INT-2 (intermediate-2) or higher (the category above INT-2).

Centers

Active Trials

—

Cancer Funding

Top Centers for Higher-Risk Myelodysplastic Syndrome (HR-MDS)(9)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Active Trials	Cancer Funding	Score
1	Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, PA NCI Comprehensive	—	—	55.6
2	The University of Texas MD Anderson Cancer CenterHouston, TX NCI Comprehensive	—	—	55.6
3	University of Colorado Cancer CenterAurora, CO NCI Comprehensive	—	—	55.6
4	Moffitt Cancer CenterTampa, FL NCI Comprehensive	—	—	55.6
5	Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive	—	—	55.6
6	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive	—	—	55.6
7	Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical	—	—	55.6
8	University of Cincinnati Cancer CenterCincinnati, OH	—	—	55.6
9	Princess Margaret Cancer CentreToronto, ON	—	—	55.6

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →